Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

[1]  N. Carr,et al.  M30 expression demonstrates apoptotic cells, correlates with in situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. , 2009, Archives of pathology & laboratory medicine.

[2]  S. Agrawal,et al.  Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics , 2004, Oncogene.

[3]  H E Gabbert,et al.  Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas , 2004, British Journal of Cancer.

[4]  T. Ebert,et al.  XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. , 2004, Human pathology.

[5]  J. Harbott,et al.  High Expression Levels of X-Linked Inhibitor of Apoptosis Protein and Survivin Correlate with Poor Overall Survival in Childhood de Novo Acute Myeloid Leukemia , 2004, Clinical Cancer Research.

[6]  R. Korneluk,et al.  The inhibitors of apoptosis: there is more to life than Bcl2 , 2003, Oncogene.

[7]  K. Shiraki,et al.  Overexpression of X-linked inhibitor of apoptosis in human hepatocellular carcinoma. , 2003, International journal of molecular medicine.

[8]  A. Vitiello,et al.  Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  S. Hamilton-Dutoit,et al.  XIAP-mediated Caspase Inhibition in Hodgkin's Lymphoma–derived B Cells , 2003, The Journal of experimental medicine.

[10]  Russell G Foster,et al.  Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. , 2003, Nucleic acids research.

[11]  V. Dragowska,et al.  Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  R. L. Hayward,et al.  Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  J. Zehnder,et al.  Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use. , 2003, American journal of clinical pathology.

[14]  J. Wood,et al.  A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera , 2003, Apoptosis.

[15]  J. Arends,et al.  Simultaneous detection of apoptosis and proliferation in colorectal carcinoma by multiparameter flow cytometry allows separation of high and low‐turnover tumors with distinct clinical outcome , 2003, Cancer.

[16]  S. Linder,et al.  Measurement of an apoptotic product in the sera of breast cancer patients. , 2003, European journal of cancer.

[17]  P. Workman.  How much gets there and what does it do?: The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. , 2003, Current pharmaceutical design.

[18]  C. Dumur,et al.  Analytical validation of a real-time reverse transcription-polymerase chain reaction quantitation of different transcripts of the Wilms' tumor suppressor gene (WT1). , 2002, Analytical biochemistry.

[19]  R. Silber,et al.  Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer , 2002, Journal of Cancer Research and Clinical Oncology.

[20]  H. Jörnvall,et al.  An immunohistochemical study of the clearance of apoptotic cellular fragments , 2002, Cellular and Molecular Life Sciences CMLS.

[21]  M. Dowsett,et al.  Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  W. Hauswirth,et al.  Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  Lennart Johansson,et al.  Apoptosis induced by low‐dose and low‐dose‐rate radiation , 2002, Cancer.

[24]  G. Salvesen,et al.  Reprieval from execution: the molecular basis of caspase inhibition. , 2002, Trends in biochemical sciences.

[25]  Krys J. Miller,et al.  Workshop on Bioanalytical Methods Validation for Macromolecules: Summary Report , 2001, Pharmaceutical Research.

[26]  R. Korneluk,et al.  XIAP: Apoptotic brake and promising therapeutic target , 2001, Apoptosis.

[27]  G. Giaccone,et al.  Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  R. Korneluk,et al.  XIAP, the guardian angel , 2001, Nature Reviews Molecular Cell Biology.

[29]  Stephanie Birkey Reffey,et al.  Characterization of XIAP-Deficient Mice , 2001, Molecular and Cellular Biology.

[30]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[31]  H. Pehamberger,et al.  Chemosensitisation of malignant melanoma by BCL2 antisense therapy , 2000, The Lancet.

[32]  R. Korneluk,et al.  Expression and genetic analysis of XIAP-associated factor 1 (XAF1) in cancer cell lines. , 2000, Genomics.

[33]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[34]  T. Kaneko,et al.  Immunohistochemical detection of cytokeratin 18 and its neo-epitope in human salivary glands and pleomorphic adenomas. , 2000, Anticancer research.

[35]  J C Reed,et al.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  B. Persson,et al.  Immunocytochemical detection and mapping of a cytokeratin 18 neo‐epitope exposed during early apoptosis , 1999, The Journal of pathology.

[37]  A. MacKenzie,et al.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.

[38]  Clemencia Pinilla,et al.  Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. , 2004, Cancer cell.

[39]  Hao Wu,et al.  Antagonizing XIAP-mediated caspase-3 inhibition. Achilles' heel of cancers? , 2004, Cancer cell.

[40]  V. Bilim,et al.  Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug‐resistant TCC in vitro , 2003, International journal of cancer.

[41]  B. Huppertz,et al.  Expression of a cytokeratin 18 neo-epitope is a specific marker for trophoblast apoptosis in human placenta. , 2001, Placenta.